ProCE Banner Activity

CE / CME

Advances in Treating Tardive Dyskinesia

Multimedia
In this interactive recording of a live CCO webinar, John M. Kane, MD, discusses risk factors and contributors to tardive dyskinesia and approved agents for tardive dyskinesia treatments.

Physician Assistants/Physician Associates: 1.00 hours of AAPA Category 1 CME credit

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Nurses: 1.00 Nursing contact hour

Released: January 20, 2022

Expiration: January 19, 2023

No longer available for credit.

Share

Faculty

John M. Kane

John M. Kane, MD

Vice President for Behavioral Health Services
Northwell Health
Chairman of Psychiatry
Zucker Hillside Hospital
Queens, New York
Chairman of Psychiatry
Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
Hempstead, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Neurocrine Biosciences

Target Audience

This program is intended for a multidisciplinary audience of neurologists, primary care physicians, nurses, physician assistants, and other members of the healthcare team involved in the management of patients with movement disorders.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • List risk factors and contributors to tardive dyskinesia
  • Compare and contrast approved agents for tardive dyskinesia treatments
  • Identify clinical features of tardive dyskinesia

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

John M. Kane, MD

Vice President for Behavioral Health Services
Northwell Health
Chairman of Psychiatry
Zucker Hillside Hospital
Queens, New York
Chairman of Psychiatry
Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
Hempstead, New York

John M. Kane, MD, has disclosed that he has received funds for research support from H. Lundbeck, Janssen Pharmaceuticals, and Otsuka; has received consulting fees from Alkermes, Allergan, Dainippon Sumitomo, H. Lundbeck, Intra-Cellular Therapies, Janssen Pharmaceuticals, LB Pharmaceuticals, Lyndra, Merck, Neurocrine Biosciences, Otsuka, Reviva, Roche, Saladex, Sunovion, Takeda, and Teva; has ownership interest in LB Pharmaceuticals, Merck, Minerva, and North Shore Therapeutics; and has received fees for non-CME/CE services from Dainippon Sumitomo, H. Lundbeck, Janssen Pharmaceuticals, and Otsuka.

Staff Disclosure

Staff

Mark Christiansen, PhD, PA-C

Mark Christiansen, PA-C, has no relevant conflicts of interest to report.

Aditi Nadkarni, PhD

Aditi Nadkarni, PhD, has no relevant conflicts of interest to report.

Lisa Phipps, PharmD, PhD

Director, Science and Strategy, Neuroscience

Lisa Phipps, PharmD, PhD, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC

Julie Skowronski, NP, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until January 19, 2023. PAs should only claim commensurate with the extent of their participation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 20, 2022, through January 19, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70.00% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, competence, and performance of learners to assess diagnostic considerations and new and emerging therapies for the treatment of movement disorders.